We are live on
!
Find out more
FP
Flagship Pioneering Portfolio holdings
AUM
$1.54B
1-Year Est. Return
86.39%
This Fund
S&P 500
This Quarter
Est. Return
-9.55%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$307M
AUM Growth
-$58.7M
(-16%)
Cap. Flow
-$19.7M
Cap. Flow
% of AUM
-6.42%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
3
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cartesian Therapeutics
RNAC
|
+$16.1M |
| 2 |
CARM
Carisma Therapeutics
CARM
|
+$2.27M |
| 3 |
TTOO
T2 Biosystems, Inc
TTOO
|
+$1.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
SPC
AWC
SMC
LCM
BOF
KCM
CP
HCM
Flagship Pioneering's Q4 2016 Portfolio in Review
As of Q4 2016, Flagship Pioneering held 7 positions worth $307M, down 16% from $366M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Flagship Pioneering withdrew a net $19.7M in Q4 2016, reducing 3 holdings. Its largest reduction was Cartesian Therapeutics, cutting an estimated $16.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Flagship Pioneering's biggest Q4 2016 reduction was Cartesian Therapeutics, cutting an estimated $16.1M.
- Flagship Pioneering's ten largest holdings make up 100% of its $307M portfolio in Q4 2016.
- Flagship Pioneering opened 0 new positions and closed 0 in Q4 2016.
- Flagship Pioneering's portfolio value fell 16% quarter-over-quarter to $307M.
Based on Flagship Pioneering's 13F filing for Q4 2016, filed 13 Feb 2017.